Vertex Stock Is Down. Its Painkiller Could Spark Big Gains.

Disappointment about the construction of a drug trial has caused Vertex stock to fall. Better times may be ahead.

Related Keywords

San Diego , California , United States , Salveen Richter , Danielle Brill , Goldman Richter , Jacob Sonenshine , Raymond James , Brian Abrahams , Evan Seigerman , Polaris Market Research , Courtesy Vertex Pharmaceuticals Incorporated , Goldman Sachs , Vertex Pharmaceuticals , Polaris Market , Cystic Fibrosis , Article Normal , Pharmaceuticals , Analgesics , Scientific Research Services , Healthcare Life Sciences , Business Consumer Services , Specialized Drugs Medications , Medical Research Services , Drug Discovery Development , Healthcare Support Services , Diagnostic Medical Research Services , Financial Performance , Corporate Industrial News , Content Types , Factiva Filters , C Amp Ampe Industry News Filter , Synd , The Trader , Biotech And Pharma , Vrtx , Vertex , S Amp Ampp 500 Index , Spx , Corporate , Industrial News , Healthcare , Life Sciences , Business , Consumer Services , Specialized Drugs , Medications , Drug Discovery , Development , Diagnostic ,